Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Jtc Plc LSE:JTC London Ordinary Share JE00BF4X3P53 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 490.00 9,186 16:35:16
Bid Price Offer Price High Price Low Price Open Price
479.00 487.00 493.00 474.00 474.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Financial 99.27 17.64 15.43 31.8 567
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:16 UT 3,008 490.00 GBX

Jtc (JTC) Latest News

More Jtc News
Jtc Takeover Rumours

Jtc (JTC) Discussions and Chat

Jtc Forums and Chat

Date Time Title Posts
14/8/202023:02JTCod's Blog87,676
31/7/202008:22JTC Group IPO March 18 6
19/2/200122:18JTC - up 20% wow . nm3

Add a New Thread

Jtc (JTC) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-08-14 15:35:16490.003,00814,739.20UT
2020-08-14 15:29:59487.001048.70AT
2020-08-14 15:29:56487.00524.35AT
2020-08-14 15:29:56487.0058282.46AT
2020-08-14 15:29:56487.0042204.54AT
View all Jtc trades in real-time

Jtc (JTC) Top Chat Posts

DateSubject
14/8/2020
09:20
Jtc Daily Update: Jtc Plc is listed in the General Financial sector of the London Stock Exchange with ticker JTC. The last closing price for Jtc was 490p.
Jtc Plc has a 4 week average price of 465p and a 12 week average price of 430p.
The 1 year high share price is 499p while the 1 year low share price is currently 280p.
There are currently 115,775,351 shares in issue and the average daily traded volume is 104,308 shares. The market capitalisation of Jtc Plc is £567,299,219.90.
11/8/2020
05:17
3ootuk: Hong Kong crackdown: After the Chinese arrest pro-democracy Apple Daily owner Jimmy Lai, the share price soars 300% as people buy shares as a signal of their support for him. One wonders whether the Chinese authorities will now go after New large shareholders, or whether gamblers will buy shares in other prodemicracy companies hoping their ceo gets arrested too.
22/7/2020
10:00
7kiwi: It’s worth looking at the robintrack ( htTps://robintrack.net/ ) data a bit more closely. First Tesla, where it looks like there’s a strong correlation between the number of users and share price. Rising from c. 80K users when the price was ~$330 to nearly 500K users now the price is up above $1,600. Now let’s take a look at a few precious metals tickers. GLD Gold ETF; GDX gold miners ETF; SLV silver ETF and SIL silver miners ETF. Strongly growing user base alongside gold’s rise. Note GLD is now the 260th most popular share on RH. Now GDX: Again, a strong correlation, with the number of users now starting to outstrip the price. Similar story for SLV and SIL: Interest in silver and silver miners seems to be rising very strongly, albeit from a low base. Of course, the rising number of users isn’t always an indication of share price and the chart for Ford testifies. But there’s perhaps some mileage in the notion that RobinHood users may start to drive the precious metals complex – the overall market cap isn’t particularly large, so a surge of interest could be explosive.
26/6/2020
07:53
chestnuts: Jtc Valuations of gold using fundies Just look at apple its a phone but you would think it was only technology in the world by looking at its share price Amazon its a ware house with good software but looks at its share price Bitcoin well what do i say about this Maybe you are looking at it the wrong way its the value of paper money you should look at. Gold, fear will drive the price and nothing else and fear is probably the biggest emotion and a bit of greed
24/6/2020
13:32
spittingbarrel: mro JTC - This whole conspiracy theory surrounding the gold price is something I really struggle to believe, I put it in the same basket as people who blame market makers when a share price isn't going their way. From my own experience you can only manipulate the price of anything for a very short time, not for years on end as the gold bugs would have you believe.
22/6/2020
12:35
jtcod: The interesting thing about Wirecard share price is that it had been falling for almost 2 years despite earnings more than doubling and overall stock markets rising. It makes me wonder if some city institutions already knew things were not adding up. Share Price Chart shows continued fall from August 2018 Https://tools.morningstar.co.uk/ukp/stockreport/default.aspx?SecurityToken=0P00007O1V%5D3%5D0%5DE0WWE%24%24ALL Note that earnings had doubled between 2016 and 2018. Https://tools.morningstar.co.uk/ukp/stockreport/default.aspx?tab=10&vw=is&SecurityToken=0P00009RB8%5D3%5D0%5DE0WWE%24%24ALL&Id=0P00009RB8&ClientFund=0&CurrencyId=BAS Q3 2019 Revenue up 37.7% and EBITDA too Https://ir.wirecard.com/download/companies/wirecard/Quarterly%20Reports/DE0007472060-Q3-2019-EQ-E-00.pdf
14/6/2020
10:09
the stigologist: I have taken the time to annotate Physiomics recent RNS regarding a Fundraise (27th May 2020). My notes are in blue text The fundraise level was at 3.5p but the shares closed this week close to 5p which represents, I believe, evidence of a well executed Fundraise because it seems there was little retail/bucket shop involvement and any Institutions partaking seem to be buying in the secondary market providing a strong underlying bid to the stock. Company : Physiomics Ticker : PYC Share Price : 4.70p Shares o/s : 95.6m Market Cap : £4.5m Cash : £1.2m (comprising £0.4m at y/e 2019 + Placing proceeds of £0.8m) Revenue (CY 2019) : £0.8m Price/Revenue : 5.5x htTps://investegate.co.uk/physiomics-plc--pyc-/rns/fundraise/202005270700070019O/ Physiomics completes £0.83m (gross) fundraise to fund growth opportunities Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has completed a placing and subscription, conditional on Admission, to raise approximately £828,750 (gross) from the issue of 23,678,571 new ordinary shares of 0.4p each ("Ordinary Shares") at an issue price of 3.5p per share, through Hybridan LLP (the "Fundraise"). In the last few years, the Company has made significant progress, including: • 70% compounded annual growth in total income FY 2017- 2019, culminating in its highest ever total income in FY 2019 of £783k • >£1m of contracts announced with Merck KGaA since master services agreement announced in November 2017 • Significant new clients CellCentric Ltd (Apr 2018) and Bicycle Therapeutics plc (June 2019) added and repeat contracts signed with both • Completion of a second Innovate UK grant project focused on personalised treatment of advanced prostate cancer (May 2019) and subsequent presentation of results at NIHR event at Royal Marsden Hospital • Award of NIHR i4i grant (March 2020) to undertake an observational trial to generate data in support of personalised dosing tool in advanced prostate cancer • Entering into discussions with companies with an established presence in the field of personalised medicine with a view to exploring how its technology could be commercialised [NOTE : Of the 6 bullet points 3 are related to Personalised Medicine. Physiomics comparitors in its core M&S business are valued at 15-30x Revenue ! BUT Companies in the Personalised Medicine AI/ML space can be valued at HUNDREDS of Millions e.g. Google took over Deepmind for $500m in 2014 ; Benevolent AI is a £1bn+ Unicorn)] On 3 March 2020, the Company announced, as part of its unaudited interim results statement, that it held cash and cash equivalents of £434k as at 31 December 2019 and that it had achieved a small positive cash inflow for the six months ended on the same date. On 19 March 2020, the Company further confirmed that it had a strong pipeline of work and the Directors believe that this has been further strengthened since that announcement. [NOTE : Physiomics already had CASH and was CASHFLOW positive so why raise money ? In my experience when Companies with enough cash raise money it's because a Large Potential Customer is considering a large contract and they want to be sure that the much smaller player will be around to service them in ANY CIRCUMSTANCES so require evidence of a significantly stronger Balance Sheet... and guess what...] In this regard, in the last two working days, the Company has received a strong indication that a significant contract is likely to be signed with a new large pharmaceutical client, with which it has been in discussions since late 2019. While is it still possible that the potential new client could withdraw, it is the Directors' opinion that this is unlikely. Should the contract be signed, the work is expected to take two of our technical staff around five months to complete. [NOTE : Physiomics main employees all have backgrounds with GSK and AZN which could point to the 'Large Pharma' being one of those ? There are c.50 Large Pharmas worldwide and outsourcing of specialist but non-core functions like Modelling & Simulation is a big growth industry so even if it isn't GSK or AZN this time, I would expect them to get involved later. One of the major advantages of PYC tech is ability to model combination treatments. Interesting in this regard that PYC's existing Big Pharma customer Merck has major collaborations with Big Pharma like GSK and Pfizer combining treatments in the exact Immuno-oncology space Physiomics software plays into] In order to further develop its business, the Company is raising funds through the Fundraise to enable it to carry out activities including increasing its sales & marketing spend, recruiting a further member of its technical team and further investing in its personalised medicine technology as well as for general working capital purposes. Director Participation in the Fundraise Dr Jim Millen (CEO), Dr Paul Harper (Chairman) and Dr Christophe Chassagnole (COO) have participated in the Fundraise in the amounts of £3,000, £5,000 and £3,000 respectively (the "Directors' Participation") and will be issued 85,715 Ordinary Shares, 142,857 Ordinary Shares and 85,715 Ordinary Shares respectively. On Admission, Dr Millen, Dr Harper and Dr Chassagnole will be interested in, in aggregate, 530,356, 668,564 and 602,723 Ordinary Shares respectively, representing 0.55%, 0.70% and 0.63%, of the Company's then enlarged issued share capital. [NOTE : This is the first time I can recall that ALL Physiomics Directors participated with their own money in a Placing. Some have made derogatory comments about the 'size' of the involvement. Fact of the matter is many People do not have a lot of spare cash to throw at Investments, one would imagine Directors already have exposure to PYC they should if anything diversify not concentrate exposure, however Management collectively own Shares and Options exceeding 6% of the Company so they are well incentivised and aligned with shareholders] Dr Jim Millen, CEO said: "We are delighted by the response to this over-subscribed fundraise. We thank our current shareholders for their continued support and have achieved another milestone by welcoming our first small-cap institutional fund onto the register. We believe this is reflective of our strong commercial traction over the last four years. Our team is committed to continuing to support global pharma and biotech companies in their drug discovery and development endeavours, and these funds will be mainly focused on growing our already strong pipeline of new business opportunities. I look forward to continuing to update shareholders on our progress."
20/5/2020
00:15
jtcod: Are Britain's banks strong enough for coronavirus?By Howard MustoeBusiness reporter8 minutes agoRecently the share prices of the UK's largest banks have collapsed, in common with those of many other companies.Banks such as RBS, Barclays and HSBC have seen their share price fall to levels not seen since the 2008 financial crisis.Some market-watchers suspect the sellers know something we don't, but others suggest the banks are in fact much stronger compared with 12 years ago.https://www.bbc.co.uk/news/business-52691369
19/4/2020
08:41
the stigologist: Howard Stanley Marks, the billionaire serial investor and founder of Oaktree Capital Management, once opined that: "When looking for the best stocks to buy, it pays to follow the money.” Indeed, investing alongside some of the world’s wealthiest can be very profitable. Take 4D Pharma (DDDD) for example; the London-listed pharmaceutical company (specialising in the development of live biotherapeutic products) currently boasts City heavyweight Richard Griffiths as its largest shareholder. The extremely well-heeled (estimated net worth of circa £300m) serial investor, who carved out a hugely successful business advising small and medium-sized companies, owns close to 14% of the company and is one of the most highly regarded investors in the UK. Known for his innate ability to unearth mispriced opportunities, Mr Griffiths is one of those high-net-worth investors who prefer to keep things pretty simple; invest in well-run companies, with significant growth potential, and that sport a substantial discount to NAV. Pretty simple. Thus, cue 4D Pharma (DDDD). The Leeds-based pharmaceutical company, currently spearheading a revolutionary new class of medicines called Live Biotherapeutics, has four, advanced, clinical-stage programmes underway in immuno-oncology, IBS, asthma and IBD. However, there’s a problem. The recent stock market rout has given rise to a staggering, and wholly unwarranted, share price dislocation that, frankly, beggars belief. Here’s why; • On January 10, 2020, 4D Pharma had cash and cash equivalents of circa £3.5 million (down from £12.9m at July 01, 2019). • On February 18, 2020, 4D Pharma raised gross proceeds of £22m at 50p per share. • On March 01, 2020, 4D Pharma had cash and cash equivalents of circa £23.5 million. • By March 18, 2020, 4D Pharma’s BOD had garnered some serious ‘skin in the game’; all three directors collectively owned 22% (24,091,936 shares) of the company! • On March 18, 2020, 4D Pharma delivered the FIRST global clinical confirmation of a live biotherapeutic product initiating a response in cancer patients; evidence of tumour shrinkage and no drug-related adverse events were observed. Overall, 51% reduction in target tumours was observed. • The company’s next significant readout (MRx0518 Phase I/II combination study with Keytruda®), which could trigger a material share price re-rate, is expected this Quarter (around May 2020). So, with a current market cap of £43m (40p), and less cash of £23m, means the market is valuing the company’s incredibly advanced and highly promising stable of drug candidates at c.£20m! Yes, feel free to bark the unsavoury but apt remark, “What the ….!” And yes, the stock market is not always the perfect arbiter of value. However, for as sure as night follows day, the market will soon move to correct the gross mispricing. In the meantime, the recently-released clinical data for the company’s lead oncology candidate may help to explain why Griffiths, the BOD, Invesco, and Henderson continue to clutch onto their 14%, 22%, 8.5%, and 3% stakes respectively.
05/4/2020
13:25
the stigologist: Howard Stanley Marks, the billionaire serial investor and founder of Oaktree Capital Management, once opined that: "When looking for the best stocks to buy, it pays to follow the money.” Indeed, investing alongside some of the world’s wealthiest can be very profitable. Take 4D Pharma (DDDD) for example; the London-listed pharmaceutical company (specialising in the development of live biotherapeutic products) currently boasts City heavyweight Richard Griffiths as its largest shareholder. The extremely well-heeled (estimated net worth of circa £300m) serial investor, who carved out a hugely successful business advising small and medium-sized companies, owns close to 14% of the company and is one of the most highly regarded investors in the UK. Known for his innate ability to unearth mispriced opportunities, Mr Griffiths is one of those high-net-worth investors who prefer to keep things pretty simple; invest in well-run companies, with significant growth potential, and that sport a substantial discount to NAV. Pretty simple. Thus, cue 4D Pharma (DDDD). The Leeds-based pharmaceutical company, currently spearheading a revolutionary new class of medicines called Live Biotherapeutics, has four, advanced, clinical-stage programmes underway in immuno-oncology, IBS, asthma and IBD. However, there’s a problem. The recent stock market rout has given rise to a staggering, and wholly unwarranted, share price dislocation that, frankly, beggars belief. Here’s why; • On January 10, 2020, 4D Pharma had cash and cash equivalents of circa £3.5 million (down from £12.9m at July 01, 2019). • On February 18, 2020, 4D Pharma raised gross proceeds of £22m at 50p per share. • On March 01, 2020, 4D Pharma had cash and cash equivalents of circa £23.5 million. • By March 18, 2020, 4D Pharma’s BOD had garnered some serious ‘skin in the game’; all three directors collectively owned 22% (24,091,936 shares) of the company! • On March 18, 2020, 4D Pharma delivered the FIRST global clinical confirmation of a live biotherapeutic product initiating a response in cancer patients; evidence of tumour shrinkage and no drug-related adverse events were observed. Overall, 51% reduction in target tumours was observed. • The company’s first significant readout (Blautix® Phase II interim analysis), which is likely to trigger a material share price re-rate, is expected this Quarter (April – early Q2 2020). • The company’s second significant readout (MRx0518 Phase I/II combination study with Keytruda®), which is also likely to trigger a material share price re-rate, is expected this Quarter (around May 2020). So, with a current market cap of £28m (27p), and less cash of £23m, means the market is valuing the company’s incredibly advanced and highly promising stable of drug candidates at c.£5m! Yes, feel free to bark the unsavoury but apt remark, “What the ….!” And yes, the stock market is not always the perfect arbiter of value. However, for as sure as night follows day, the market will soon move to correct the gross mispricing. In the meantime, the recently-released clinical data for the company’s lead oncology candidate may help to explain why Griffiths, the BOD, Invesco, and Henderson continue to clutch onto their 14%, 22%, 8.5%, and 3% stakes respectively.
12/3/2020
14:35
lefrene: JTC, I noticed in Trumps speech last night that airlines and cruise companies were to be helped out. Yes a lot of that QE money has gone to companies that used the money to buy back shares to boost the share price, just so that big bonuses based on company share price could kick in! How very very convenient that we now have a global 'pan-demic' that provides the perfect excuse to do whatever you like, to bail out the mess!!
Jtc share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
JTC
Jtc
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200814 23:03:29